Healthcare -
Biotechnology - NASDAQ - US
$ 42.02
-6.46 %
$ 3.35 B
Market Cap
-11.21
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Akero Therapeutics, Inc.
| Net Income | -252 M |
| Depreciation & Amortization | -13.1 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 29.7 M |
| Change in Working Capital | 3 M |
| Others | 3.35 M |
| Free Cash Flow | -230 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||
| Net Income | (252.1) | (151.8) | (112.0) | (100.8) | (79.2) | (43.8) | (81.7) | (4.6) |
| Depreciation & Amortization | (13.1) | 29 K | 43 K | 41 K | 17 K | (0.1) | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 1.1 | 83 K | 0.1 | 0 | 0 |
| Stock Based Compensation | 29.7 | 21.5 | 23.2 | 10.1 | 6.0 | 1.8 | 0.1 | 0 |
| Other Operating Activities | 2.4 | (8.5) | 0.7 | 0.2 | 0.2 | (0.1) | 75.9 | 60 K |
| Change in Working Capital | 3.0 | (6.7) | (4.5) | 9.7 | 2.1 | 6.5 | 1.1 | 0.2 |
| Cash From Operations | (230.1) | (145.4) | (92.5) | (79.7) | (70.8) | (35.6) | (4.6) | (4.4) |
| INVESTING CASH FLOW | ||||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | (0.1) | 0 | (5.0) | 0 |
| Other Items | (109.7) | (223.6) | (63.8) | 42.3 | (9.6) | (71.5) | 0 | 0 |
| Cash From Investing Activities | (109.7) | (223.6) | (63.8) | 42.3 | (9.8) | (71.5) | (5.0) | 0 |
| FINANCING CASH FLOW | ||||||||
| Common Stock Repurchased | 0.5 | 0 | 0 | 0.4 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 10.0 | 15.0 | 10.0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 12.8 | 2.9 | 4.4 | 0.6 | 0.6 | 0.5 | 85.0 | 5.0 |
| Cash From Financing Activities | 445.8 | 353.3 | 255.6 | 0.6 | 203.1 | 96.0 | 85.0 | 5.0 |
| CHANGE IN CASH | ||||||||
| Net Change In Cash | 106.0 | (15.7) | 99.3 | (36.8) | 122.5 | (11.2) | 75.4 | 0.6 |
| FREE CASH FLOW | ||||||||
| Free Cash Flow | (230.1) | (145.4) | (92.5) | (79.7) | (71.0) | (35.6) | (9.6) | (4.4) |